Effects of irbesartan on 24-h blood pressure changes and urinary albumin levels in Japanese outpatients
T Arai, M Senda, H Yokoyama… - ExpErimEntal and …, 2010 - spandidos-publications.com
In Japan, ambulatory blood pressure monitoring (ABPM) became covered by health
insurance in April 2008. In The Japanese Society of Hypertension Guidelines for the …
insurance in April 2008. In The Japanese Society of Hypertension Guidelines for the …
Development and Validation of a Rat Model for Examining the AT [subscript] 1 [/subscript] and ET [subscript] A [/subscript] Receptor-Blocking Activity of Dual AT …
Background: Hypertension is a multifactorial disease, with angiotensin II (Ang II) as the
established target of pharmacological intervention. However, there has been increasing …
established target of pharmacological intervention. However, there has been increasing …
Development and Validation of a Rat Model for Examining the AT1 and ETA Receptor-Blocking Activity of Dual AT1 and ETA Receptor Blockers
Background: Hypertension is a multifactorial disease, with angiotensin II (Ang II) as the
established target of pharmacological intervention. However, there has been increasing …
established target of pharmacological intervention. However, there has been increasing …
1. CLINICAL PHARMACOLOGY OF CURRENT ANTIHYPERTENSIVE DRUGS
A IN'T VELD… - Antihypertensive …, 1997 - books.google.com
Diuretics are used in the treatment of hypertension for over 30 years and still are the most
frequently prescribed antihypertensive drugs worldwide. Diuretics are inexpensive, well …
frequently prescribed antihypertensive drugs worldwide. Diuretics are inexpensive, well …
Angiotensin II (Typ-1)-Rezeptorblocker in der Behandlung der chronischen Herzinsuffizienz
K Huber, R Pichler - Journal für Kardiologie-Austrian Journal of Cardiology, 1999 - kup.at
Angiotensin II-Typ 1-Rezeptor-Blocker (AT1-Blocker) kamen in den vergangenen Jahren
zunehmend in der Behandlung der chronischen Herzinsuffizienz zum Einsatz. Dabei …
zunehmend in der Behandlung der chronischen Herzinsuffizienz zum Einsatz. Dabei …
The Site of Angiotensin Generatlon: Focus on the Heart
LM De Lannoy, AHJ Danser - Angiotensin II Receptor Blockade …, 1997 - Springer
All renin-angiotensin system (RAS) components are present in cardiac tissue, and both
angiotensin (Ang) I and II appear to be produced in the heart, either in cardiac interstitial …
angiotensin (Ang) I and II appear to be produced in the heart, either in cardiac interstitial …
Consenso Colombiano sobre Antagonistas de los Receptores de Angiotensina II (ARA II)
AM Colombiana - Acta Médica Colombiana, 2002 - actamedicacolombiana.com
Los estudios sobre el SRA, se iniciaron en el siglo XIX siendo la base de este sistema el
descubrimiento de la renina por Tigersted y Bergman en 1898, el cual se convirtió en la …
descubrimiento de la renina por Tigersted y Bergman en 1898, el cual se convirtió en la …
長時間作用型ARB イルベサルタン(イルベタン® 錠50 mg, イルベタン® 錠100 mg) の薬理作用と臨床特性
有吉祐亮， 水本継吾 - 日本薬理学雑誌, 2009 - jstage.jst.go.jp
抄録 イルベサルタン (イルベタン®) は, 仏 Sanofi 社 (現 sanofi-aventis 社) が創出した
アンジオテンシン II (AII) タイプ 1 受容体 (AT 1) 拮抗薬 (ARB) で, それ自体が活性物質であり …
アンジオテンシン II (AII) タイプ 1 受容体 (AT 1) 拮抗薬 (ARB) で, それ自体が活性物質であり …
[引用][C] A Review of the New Angiotensin II‐Receptor Antagonist Irbesartan
JR Powell, RA Reeves, MR Marino… - Cardiovascular drug …, 1998 - Wiley Online Library
The renin-angiotensin system (RAS) plays a key role in regulating blood pressure (BP) and
fluid and electrolyte balance in the body. Strategies to inhibit the RAS have been achieved …
fluid and electrolyte balance in the body. Strategies to inhibit the RAS have been achieved …